Evidence map›Paper›PMID 37308104›Full record

ArticleThe American journal of tropical medicine and hygiene2023

Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.

Laura E Adams, Matt D T Hitchings, Freddy A Medina, Dania M Rodriguez, Liliana Sánchez-González, Hannah Moore, Stephen S Whitehead, Jorge L Muñoz-Jordán, Vanessa Rivera-Amill, Gabriela Paz-Bailey

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laura E AdamsDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Matt D T HitchingsUniversity of Florida, Gainesville, Florida.
Freddy A MedinaDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Dania M RodriguezDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Liliana Sánchez-GonzálezDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Hannah MooreUniversity of Georgia, Athens, Georgia.
Stephen S WhiteheadLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Jorge L Muñoz-JordánDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Vanessa Rivera-AmillPonce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico.
Gabriela Paz-BaileyDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.

Funding

Laboratory And Preclinical Studies Of FlavivirusesZIAAI000891 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$17.5M
NCEZID CDC HHS U01 CK000437NCEZID CDC HHS U01 CK000580
6 · The paper itself

Abstract

Limited dengue virus (DENV) seroprevalence estimates are available for Puerto Rico, which are needed to inform the potential use and cost-effectiveness of DENV vaccines. The Communities Organized to Prevent Arboviruses (COPA) is a cohort study initiated in 2018 in Ponce, Puerto Rico, to assess arboviral disease risk and provide a platform to evaluate interventions. We recruited participants from households in 38 study clusters, who were interviewed and provided a serum specimen. Specimens from 713 children aged 1 to 16 years during the first year of COPA were tested for the four DENV serotypes and ZIKV using a focus reduction neutralization assay. We assessed the seroprevalence of DENV and ZIKV by age and developed a catalytic model from seroprevalence and dengue surveillance data to estimate the force of infection for DENV during 2003-2018. Overall, 37% (n = 267) were seropositive for DENV; seroprevalence was 9% (11/128) among children aged 1 to 8 years and 44% (256/585) among children aged 9 to 16 years, exceeding the threshold over which DENV vaccination is deemed cost-effective. A total of 33% were seropositive for ZIKV, including 15% among children aged 0 to 8 years and 37% among children aged 9 to 16 years. The highest force of infection occurred in 2007, 2010, and 2012-2013, with low levels of transmission from 2016 to 2018. A higher proportion of children had evidence of multitypic DENV infection than expected, suggesting high heterogeneity in DENV risk in this setting.

Indexed as

DengueDengue VaccinesDengue VirusZika VirusZika Virus InfectionAntibodies, ViralChildCohort StudiesHumansPuerto RicoSeroepidemiologic StudiesAntibodies, ViralDengue Vaccines

Identifiers

PMID37308104
PMCPMC10397428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.